AXON Trial Agreement

City of El Mirage — Regular Meeting (2022-02-01)

View PDF Item 7 Meeting page

Extracted text (via pymupdf) 23060 characters
Field Trial Agreement 
 
 
Title: General Field Trial Agreement for All Products (90 Days) 
 Department: Legal 
 
Version: 15.0 
 Release Date: 5/21/2021 
Page 1 of 6 
This Agreement grants the right to use the Axon Enterprise, Inc. (“Axon”) Trial 
Kit(s) identified in this Agreement to your law enforcement agency (“Agency”) 
on loan and free of charge for a trial and evaluation of the Trial Kit by Agency.1 
The Trial Period is 90 days unless extended by Axon. 
1. Trial Kit. The Trial Kit may include the following: 
Qty._____ 
74016 – Axon Body 2 T&E Kit 
Qty._____ 
70042 – Axon Body 2 Dock, Single Camera Bay 
Qty._____ 
70043 – Axon Body 2 Dock, 6-Camera Bay 
Qty._____ 
73210 – Axon Body 3 T&E Kit 
Qty._____ 
74213 – Axon Body 3 – 1 Bay Dock, T&E 
Qty._____ 
74212 – Axon Body 3 – 8 Bay Dock, T&E 
Qty._____ 
11530 – Axon Flex 2 T&E Kit  
Qty._____ 
11541 – Axon Flex 2 Single-Bay Dock 
Qty._____ 
11542 – Axon Flex 2 Six-Bay Dock 
Qty._____ 
20025 – TASER 7 CEW  
Qty._____ 
20026 – TASER 7 Dock 
Qty._____ 
80088 – TASER 7 T&E Target 
Qty._____ 
11007 – X26P CEW T&E Kit 
Qty._____ 
22004 – X2 CEW T&E Kit 
Qty._____ 
71089 – Axon Fleet 2 Kit 
Qty._____ 
Axon Fleet 3 T&E Kit 
Qty._____ 
11524 – Axon Signal 
Qty._____ 
11559 – T&E, PPM, Signal 
Qty._____ 
71043 – Axon Signal Sidearm 
Qty. _____ 
Axon Evidence (Evidence.com)  
Qty. _____ 
Fleet in a Box 
Qty. _____ 
Trial - Axon Redaction Assistant 
Qty. _____ 
Trial – Axon Performance  
Qty. _____ 
Trial – Axon Auto-Tagging 
Qty. _____ 
Trial - Axon Citizen for Communities 
Qty. _____ 
Trial – Axon Respond Device License + 
Qty. _____ 
Trial – Axon Air License 
Qty. _____ 
20209 - TASER 7 CQ T&E Handle Kit 
Qty. _____ 
50031 - T&E - Axon Interview Mobile Kit 
Qty. _____ 
20269 - VR Empathy Development Training T&E Kit 
Qty. _____ 
Trial – Axon Auto-Transcribe 
Qty. _____ 
Trial – Third Party Video Support 
 
Axon may limit the number of Trial Kits Agency receives. Axon may supply a 
refurbished Trial Kit. Axon’s warranty, limitations and releases for the Trial Kits 
is applicable and available on Axon’s website at www.axon.com/legal. 
2. Agency Obligations. Agency agrees to only use the Trial Kit for trial and 
evaluation purposes and will not: (a) reproduce or modify the Trial Kit; or (b) rent, 
sell, lease or otherwise transfer the Trial Kit. Agency agrees to comply with all 
Axon training materials regarding the Trial Kit during the Trial Period. For Trial 
Kits that contain a conducted energy weapon (“CEW”), Agency agrees that every 
employee or agent that carries, uses, or deploys the CEW during the Trial Period 
will have: (a) obtained certification as a TASER CEW user or instructor; and (b) 
completed any training specific to the CEW model by utilizing the current TASER 
CEW lesson plan. Upon request by Axon, Agency agrees to cooperate and 
participate in a case study involving the Trial Kit and Agency’s use of the Trial 
Kit. Agency agrees that Axon will have a non-exclusive, perpetual license to 
utilize the results and any report or publication resulting from the case study in 
Axon’s training, markets and sales materials. If Agency’s trial includes Axon 
Fleet, and Agency is using wireless offload, then Agency is responsible for 
providing either a cellular SIM card or wireless network at Agency. For use of 
Axon Performance, Axon may need to access and store Agency’s call for service 
records. 
 
3. Return of Product. Agency agrees to return the Trial Kit to Axon within 10 
days after the end of the Trial Period, excluding used CEW cartridges. If any 
individual component of the Trial Kit is not returned to Axon at the end of the 
Trial Period, Axon will invoice Agency the MSRP of the unreturned items in the 
Trial Kit(s). Agency agrees to pay the invoice along with any applicable taxes 
and shipping. Agency will return the Trial Kit to Axon in good working condition, 
normal wear and tear excepted. Axon may charge Agency if there is damage 
beyond normal wear and tear.  
Before Agency returns the Trial Kit, it is Agency’s responsibility to download any 
data and keep a backup copy of the data. All data stored in the Trial Kit will be 
erased upon receipt of the Trial Kit by Axon. Agency will return the Trial Kit to: 
Axon Enterprise, Inc., 17800 N. 85th Street, Scottsdale, Arizona USA 85255, 
Attention: Trial Returns. 
4. Agency Data. Within 30 days of the Trial Period ending, Agency may 
request Axon make available to Agency for download Agency data that Agency 
uploaded to Axon Evidence during the Trial Period. During the 30 days following 
this request, Agency may retrieve its data from Axon Evidence. After this 30-day 
period, Axon will have no obligation to maintain or provide any data uploaded to 
Axon Evidence and will thereafter, unless legally prohibited, delete all of this data 
in Axon’s systems or otherwise in its possession or control. 
5. Proprietary Information. Agency agrees Axon has and claims various 
proprietary rights in the hardware, firmware, software, and the integration of 
ancillary materials, knowledge, and designs that constitute the Trial Kit. Agency 
will not directly or indirectly cause any proprietary rights to be violated. 
Formal Matters. 
A. Signature. Your signature warrants and acknowledges that you are 
authorized to execute this Agreement on behalf of your Agency. 
B. Entire Agreement. This Agreement, including the attached Axon Evidence 
Terms of Use Appendix,  Axon Auto-Tagging Appendix, Axon Respond 
Appendix, Axon Auto-Transcribe Appendix, and Axon Fleet Appendix (to the 
extent such appendices are applicable), contains all the terms and conditions 
agreed on by the parties regarding the Trial Kit. Any previous agreements 
between the parties regarding a free trial of the Trial Kit are replaced by this 
Agreement. This Agreement can be modified or changed only by a written 
instrument signed by both parties. If any part of this Agreement is held indefinite, 
invalid, or otherwise unenforceable, the rest of the Agreement will continue in full 
force and effect.  
C. Relationship of the Parties. The parties are independent contractors and 
this Agreement does not create a partnership, franchise, joint venture, agency, 
fiduciary or employment relationship between the parties. 
D. Assignment. You must not, by operation of law or otherwise, assign any of 
your rights or delegate any of your obligations under this Agreement without the 
prior express written consent of Axon. 
ACCEPTED and AGREED as of_________________________, 202_ 
Agency Name: 
 
   
 
Signature:    
 
   
 
Printed Name:    
 
  
 
Title:    
 
   
 
Phone:  
 E-mail:  
 
 
1This Agreement does not cover trials or evaluations solely of any Axon beta software or firmware. 
CradlePoint is a trademark of CradlePoint, Inc. 
 
 AXON, Axon, Axon Evidence, Axon Flex, Fleet, X2, X26, TASER 7, and TASER are trademarks of Axon Enterprise, Inc., some of which are registered 
SIGN

Field Trial Agreement 
 
 
Title: General Field Trial Agreement for All Products (90 Days) 
 Department: Legal 
 
Version: 15.0 
 Release Date: 5/21/2021 
Page 2 of 6 
in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved. © 2021 Axon Enterprise, Inc. 
Axon Evidence (Evidence.com) Terms of Use Appendix 
 
1 
Definitions. 
“Agency Content” is data uploaded into, ingested by, or created in Axon Evidence within a Customer’s tenant. Agency Content includes Evidence but 
excludes Non-Content Data.  
 
“Axon Devices” means physical devices from Axon, including TASER Smart Weapons and Cartridges, Axon Docks, Axon Cameras, and Axon Signal. 
 
“Evidence” is media or multimedia uploaded into Axon Evidence as 'evidence' by a Customer. Evidence is a subset of Agency Content. 
 
“Non-Content Data” is data, configuration, and usage information about Agency’s Axon Evidence tenant, Axon Products and client software, and users 
that is transmitted or generated when using Axon Devices. Non-Content Data includes data about users captured during account management and 
customer support activities. Non-Content Data does not include Agency Content. 
 
2 
Access Rights. Agency will have access and use of Axon Evidence for the storage and management of Agency Content during the Trial Period. 
  
3 
Agency Owns Agency Content. Agency controls and owns all right, title, and interest in Agency Content. Except as outlined herein, Axon obtains no 
interest in Agency Content, and Agency Content are not business records of Axon. Agency is solely responsible for uploading, sharing, managing, and 
deleting Agency Content. Axon will have limited access to Agency Content solely for providing and supporting Axon Evidence to Agency and Agency 
end users. 
 
4 
Security. Axon will implement commercially reasonable and appropriate measures to secure Agency Content against accidental or unlawful loss, 
access or disclosure. Axon will maintain a comprehensive information security program including logical, physical access, vulnerability, risk, and 
configuration management; incident monitoring and response; encryption of uploaded digital evidence; security education; and data protection. Axon 
agrees to the Federal Bureau of Investigation Criminal Justice Information Services Security Addendum.  
 
5 
Data Privacy. Axon will not disclose Agency Content or information about Agency except as compelled by a court or administrative body or required 
by law or regulation. If Axon receives a disclosure request for Agency Content, Axon will give Agency notice so Agency may file an objection with the 
court or administrative body. Agency agrees to allow Axon access to certain information from Agency to: (a) perform troubleshooting services upon 
request or as part of regular diagnostic screening; (b) enforce this Agreement or policies governing the use of Axon Evidence; or (c) perform analytic 
and diagnostic evaluations of the systems. 
 
6 
Data Storage. Axon may transfer Agency Content to third party subcontractors for storage. Axon will determine the locations of data centers for storage 
of Agency Content. For United States agencies, Axon will ensure all Agency Content stored in Axon Evidence remains within the United States. 
Ownership of Agency Content remains with Agency.  
 
7 
Suspension of Axon Evidence Services. Axon may suspend Agency access or any end user’s right to access or use any portion or all of Axon 
Evidence immediately upon notice, in accordance with the following: the Agency or an end user’s use of or registration for the Axon Evidence Services 
(i) poses a security risk to the Axon Evidence Services or any third party, (ii) may adversely impact the Axon Evidence Services or the systems or 
content of any other customer, (iii) may subject Axon, Axon’s affiliates, or any third party to liability, or (iv) may be fraudulent. Axon will not delete any 
of Agency Content on Axon Evidence as a result of a suspension, except as specified elsewhere in this Agreement. 
 
8 
License Restrictions. Agency and Agency end users (including employees, contractors, agents, officers, volunteers, and directors), may not, or may 
not attempt to:  
8.1. 
copy, modify, tamper with, repair, or create derivative works of any part of Axon Evidence;  
8.2. 
reverse engineer, disassemble, or decompile Axon Evidence or apply any process to derive any source code included in Axon Evidence, or 
allow others to do the same;  
8.3. 
access or use Axon Evidence with the intent to gain unauthorized access, avoid incurring fees or exceeding usage limits or quotas; 
8.4. 
use trade secret information contained in Axon Evidence, except as expressly permitted in this Agreement;  
8.5. 
access Axon Evidence to build a competitive product or service or copy any features, functions, or graphics of Axon Evidence;  
8.6. 
remove, alter, or obscure any confidentiality or proprietary rights notices (including copyright and trademark notices) of Axon’s or Axon’s 
licensors on or within Axon Evidence; or  
8.7. 
use Axon Evidence to store or transmit infringing, libelous, or other unlawful or tortious material; to store or transmit material in violation of 
third-party privacy rights; or to store or transmit malicious code.

Field Trial Agreement 
 
 
Title: General Field Trial Agreement for All Products (90 Days) 
 Department: Legal 
 
Version: 15.0 
 Release Date: 5/21/2021 
Page 3 of 6 
Axon Auto-Tagging Appendix 
 
1 
Scope. Axon Auto-Tagging consists of development of a module to allow Axon Evidence to interact with Agency’s Computer-Aided Dispatch (“CAD”) 
or Records Management Systems (“RMS”). This allows end users to auto populate Axon video meta-data with a case ID, category, and location based 
on data maintained in Agency’s CAD or RMS. Agency must purchase Axon Auto-Tagging for every Axon Evidence user in Agency, even if the user 
does not have an Axon body camera. 
 
2 
Agency Responsibilities. Axon’s performance of Auto-Tagging Services requires Agency to: 
2.1. 
Make available relevant systems, including Agency’s current CAD or RMS, for assessment by Axon (including remote access if possible); 
2.2. 
Make required modifications, upgrades or alterations to Agency’s hardware, facilities, systems and networks related to Axon’s performance 
of Auto-Tagging Services; 
2.3. 
Provide access to the premises where Axon is performing Auto-Tagging Services, subject to Agency safety and security restrictions, and 
allow Axon to enter and exit the premises with laptops and materials needed to perform Auto-Tagging Services; 
2.4. 
Provide all infrastructure and software information (TCP/IP addresses, node names, network configuration) necessary for Axon to provide 
Auto-Tagging Services; 
2.5. 
Promptly install and implement any and all software updates provided by Axon; 
2.6. 
Ensure that all appropriate data backups are performed; 
2.7. 
Provide assistance, participation, and approvals in testing Auto-Tagging Services; 
2.8. 
Provide Axon with remote access to Agency’s Axon Evidence account when required; 
2.9. 
Notify Axon of any network or machine maintenance that may impact the performance of the module at Agency; and 
2.10. 
Ensure reasonable availability of knowledgeable staff and personnel to provide timely, accurate, complete, and up-to-date documentation 
and information to Axon. 
 
3 
Access to Systems. Agency authorizes Axon to access Agency’s relevant computers, network systems, and CAD or RMS solely for performing Auto-
Tagging Services. Axon will work diligently to identify as soon as reasonably practicable resources and information Axon expects to use, and will provide 
an initial list to Agency. Agency is responsible for, and assumes the risk of any problems, delays, losses, claims, or expenses resulting from the content, 
accuracy, completeness, and consistency of all data, materials, and information supplied by Agency.

Field Trial Agreement 
 
 
Title: General Field Trial Agreement for All Products (90 Days) 
 Department: Legal 
 
Version: 15.0 
 Release Date: 5/21/2021 
Page 4 of 6 
Axon Respond Appendix 
 
1 
Scope of Axon Aware. The scope of Axon Respond is to assist Agency with real-time situational awareness during critical incidents to improve officer 
safety, effectiveness, and awareness. In the event Agency uses Axon Aware outside this scope, Axon may initiate good-faith discussions with Agency 
on upgrading Agency’s Axon Respond to better meet Agency’s needs. In the event Agency does not stop using Axon Respond at the end of the Trial 
Period, Axon may charge Agency for continued use. 
 
2 
LTE Requirements. Axon Respond is only available and usable with an LTE enabled body-worn camera. Axon is not liable if Agency utilizes the LTE 
device outside of the coverage area or if the LTE carrier is unavailable. LTE coverage is only available in the United States, including any U.S. territories. 
Axon may utilize a carrier of Axon’s choice to provide LTE service. Axon may change LTE carriers during the Term without Agency’s consent. 
 
3 
Axon Respond Service Limitations. Agency acknowledges that LTE service is made available only within the operating range of the networks. Service 
may be temporarily refused, interrupted, or limited because of: (a) facilities limitations; (b) transmission limitations caused by atmospheric, terrain, other 
natural or artificial conditions adversely affecting transmission, weak batteries, system overcapacity, movement outside a service area or gaps in 
coverage in a service area and other causes reasonably outside of the carrier’s control such as intentional or negligent acts of third parties that damage 
or impair the network or disrupt service; or (c) equipment modifications, upgrades, relocations, repairs, and other similar activities necessary for the 
proper or improved operation of service. 
 
Partner networks are made available as-is and the carrier makes no warranties or representations as to the availability or quality of roaming service 
provided by carrier partners, and the carrier will not be liable in any capacity for any errors, outages, or failures of carrier partner networks. Agency 
expressly understands and agrees that it has no contractual relationship whatsoever with the underlying wireless service provider or its affiliates or 
contractors and Agency is not a third-party beneficiary of any agreement between Axon and the underlying carrier.

Field Trial Agreement 
 
 
Title: General Field Trial Agreement for All Products (90 Days) 
 Department: Legal 
 
Version: 15.0 
 Release Date: 5/21/2021 
Page 5 of 6 
Axon Auto-Transcribe Appendix 
This Appendix applies to Axon Auto-Transcribe. 
1) 
Subscription Term. If Agency purchases Axon Auto-Transcribe as part of a bundle or Axon Cloud Services license, the subscription begins on the 
later of the (1) start date of the bundle or Axon Cloud Services license term, or (2) date Axon provisions Axon Auto-Transcribe to Agency. If Agency 
purchases Axon Auto-Transcribe minutes as a standalone, the subscription begins on the date Axon provisions Axon Auto-Transcribe. 
 
Axon Auto-Transcribe minutes expire one year after being granted. 
 
If Agency cancels Auto-Transcribe services, any amounts owed by the Parties will be based on the amount of time passed under the annual 
subscription, rather than on the number of minutes used, regardless of usage.  
 
2) 
Auto-Transcribe A-La-Carte Minutes. Upon Axon granting Agency a set number of minutes, Agency may utilize Axon Auto-Transcribe, subject to 
the amounts allowed on the Quote. Agency will not have the ability to roll over unused minutes to future Auto-Transcribe terms. Axon may charge 
Agency additional fees for exceeding purchased amounts.  
 
3) 
Axon Auto-Transcribe On Demand. Upon Axon granting Agency an On Demand subscription to Axon Auto-Transcribe, Agency may utilize Axon 
Auto-Transcribe with no limit on the number of minutes. The scope of Axon Auto-Transcribe On Demand is to assist Agency with reviewing and 
transcribing individual evidence items. In the event Agency uses Axon Auto-Transcribe On Demand outside this scope, Axon may initiate good-faith 
discussions with Agency on upgrading Agency’s Axon Auto-Transcribe On Demand to better meet Agency’s needs. 
 
4) 
Warranty. Axon does not warrant accuracy of Axon Auto-Transcribe.

Field Trial Agreement 
 
 
Title: General Field Trial Agreement for All Products (90 Days) 
 Department: Legal 
 
Version: 15.0 
 Release Date: 5/21/2021 
Page 6 of 6 
Axon Fleet Appendix 
1 
Agency Responsibilities. Agency must ensure its infrastructure and vehicles adhere to the minimum requirements to operate Axon 
Fleet 2 or Axon Fleet 3 (collectively, “Axon Fleet”) as established by Axon during the qualifier call and on-site assessment at Agency 
and in any technical qualifying questions. If Agency’s representations are inaccurate, the Quote is subject to change.   
2 
Cradlepoint. If Agency purchases Cradlepoint Enterprise Cloud Manager, Agency will comply with Cradlepoint’s end user license 
agreement. The term of the Cradlepoint license may differ from the Axon Evidence Subscription. If Agency requires Cradlepoint 
support, Agency will contact Cradlepoint directly. 
3 
Third-party Installer.  Axon will not be liable for the failure of Axon Fleet hardware to operate per specifications if such failure results 
from installation not performed by, or as directed by Axon. 
4 
Wireless Offload Server. 
4.1 
License Grant. Axon grants Agency a non-exclusive, royalty-free, worldwide, perpetual license to use Wireless Offload 
Server (“WOS”). “Use” means storing, loading, installing, or executing WOS solely for data communication with Axon 
Devices for the number of licenses purchased. The WOS term begins upon the start of the Axon Evidence Subscription. 
4.2 
Restrictions. Agency may not: (a) modify, alter, tamper with, repair, or create derivative works of WOS; (b) reverse 
engineer, disassemble, or decompile WOS, apply any process to derive the source code of WOS, or allow others to do so; 
(c) access or use WOS to avoid incurring fees or exceeding usage limits; (d) copy WOS in whole or part; (e) use trade secret 
information contained in WOS; (f) resell, rent, loan or sublicense WOS; (g) access WOS to build a competitive device or 
service or copy any features, functions or graphics of WOS; or (h) remove, alter or obscure any confidentiality or proprietary 
rights notices (including copyright and trademark notices) of Axon or Axon’s licensors on or within WOS.  
4.3 
WOS Support. Upon request by Axon, Agency will provide Axon with access to Agency’s store and forward servers solely 
for troubleshooting and maintenance.  
5 
Axon Vehicle Software. 
5.1 
License Grant. Axon grants Agency a non-exclusive, royalty-free, worldwide, perpetual license to use ViewXL or Dashboard 
(collectively, “Axon Vehicle Software”.) “Use” means storing, loading, installing, or executing Axon Vehicle Software solely for 
data communication with Axon Devices. The Axon Vehicle Software term begins upon the start of the Axon Evidence 
Subscription. 
5.2 
Restrictions. Agency may not: (a) modify, alter, tamper with, repair, or create derivative works of Axon Vehicle Software; (b) 
reverse engineer, disassemble, or decompile Axon Vehicle Software, apply any process to derive the source code of Axon 
Vehicle Software, or allow others to do so; (c) access or use Axon Vehicle Software to avoid incurring fees or exceeding 
usage limits; (d) copy Axon Vehicle Software in whole or part; (e) use trade secret information contained in Axon Vehicle 
Software; (f) resell, rent, loan or sublicense Axon Vehicle Software; (g) access Axon Vehicle Software to build a competitive 
device or service or copy any features, functions or graphics of Axon Vehicle Software; or (h) remove, alter or obscure any 
confidentiality or proprietary rights notices (including copyright and trademark notices) of Axon or Axon’s licensors on or 
within Axon Vehicle Software.